Detalhe da pesquisa
1.
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
Clin Infect Dis
; 76(3): 398-407, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36210481
2.
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study.
J Viral Hepat
; 30(3): 209-222, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36302125
3.
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
J Hepatol
; 77(5): 1265-1275, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35697332
4.
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
J Hepatol
; 77(3): 642-652, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35460726
5.
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
N Engl J Med
; 388(9): 857-859, 2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36734884
6.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Hepatology
; 67(2): 505-513, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28865152
7.
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
J Med Virol
; 90(1): 109-119, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28842997
8.
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Ann Hepatol
; 17(6): 959-968, 2018 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30600291
9.
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Gastroenterology
; 145(5): 1035-1044.e5, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23924660
10.
The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
Br J Clin Pharmacol
; 75(2): 431-9, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22642697
11.
Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
Vaccine
; 41(26): 3930-3936, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37211453
12.
[Proinsulin: physiology, measurement, and interest in clinical biology]. / La pro-insuline : physiologie, dosage et intérêt en biologie clinique.
Ann Biol Clin (Paris)
; 81(5)2023 Nov 29.
Artigo
em Francês
| MEDLINE | ID: mdl-38018823
13.
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Vaccine
; 41(29): 4280-4286, 2023 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271706
14.
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Expert Rev Vaccines
; 22(1): 501-517, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246757
15.
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
Hepatology
; 54(1): 20-7, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21618566
16.
Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.
Antimicrob Agents Chemother
; 55(10): 4569-74, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21825288
17.
Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Eur J Drug Metab Pharmacokinet
; 44(1): 43-52, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29909549
18.
Infectious diarrhea in autologous stem cell transplantation: high prevalence of coccidia in a South American center.
Hematol Transfus Cell Ther
; 40(2): 132-135, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30057986
19.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
J Gastroenterol
; 53(4): 557-565, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948366
20.
Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
J Gastroenterol
; 53(5): 689, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29134328